{"id":"W3211808513","doi":"10.1182/blood-2021-154074","title":"Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blinatumomab; Rituximab; Internal medicine; Gastroenterology; Cytarabine; Chemotherapy; Surgery; Leukemia; Lymphoblastic Leukemia; Lymphoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002646661,0.0006748996,0.001724315,0.0002072528,0.0002312309,0.0008612256,0.0005919639,0.000673299,0.002116486],"category_scores_gemma":[0.00131494,0.0003378301,0.001102564,0.0003711934,0.0004191805,0.00075577,0.0002926839,0.001876233,0.000439836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004808243,"about_ca_system_score_gemma":0.0007397915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008365987,"about_ca_topic_score_gemma":0.001964133,"domain_scores_codex":[0.9994465,0.0002736764,0.00006048983,0.00006803319,0.00006253218,0.00008878812],"domain_scores_gemma":[0.9987271,0.0003181433,0.0002833708,0.0001019895,0.0001186343,0.0004507868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6488377,0.0341123,0.02601002,0.001910592,0.005915644,0.0003087012,0.0004369923,0.002398596,0.05478193,0.0002156031,0.006294243,0.2187776],"study_design_scores_gemma":[0.3777279,0.4967225,0.1014859,0.0001531765,0.005325909,0.0006685556,0.0001324144,0.0009876983,0.005114716,0.0002266608,0.01140767,0.00004684414],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871764,0.00731852,0.0006545631,0.0004471694,0.0001314749,0.001007947,0.001758016,0.00005308576,0.001452843],"genre_scores_gemma":[0.9850646,0.004396344,0.001797866,0.001094888,0.0001720097,0.001246741,0.004965469,0.00002820206,0.001233958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002646661,"threshold_uncertainty_score":0.01399702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01281744692112593,"score_gpt":0.2746609611731929,"score_spread":0.261843514252067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}